Table 3.

Results of base case cost-effectiveness of analysis

Name of strategy	Costs (US$)	Effectiveness (DALYs)	Incremental Costs	Incremental Effectiveness (DALY averted)	ICER (US$ / DALY averted)	Annual CC incidence per 100,000	Remark
Gavi vaccine price ($4.5/dose)
CS	8.00	0.00427	–	–	–	17.08	–
NS alone	10.27	0.00418	2.27	0.00009	–	16.52	Dom
CS + NV	18.23	0.00298	10.23	0.00129	7930	11.52	R
NS + NV	20.16	0.00292	1.93	0.00006	32,167	11.16	NR
Lowest vaccine price offered to public sector ($13/dose)
CS	8.05	0.00431	–	–	–	17.09	–
NS alone	10.31	0.00421	2.26	0.00010	–	16.53	Dom
CS + NV	29.76	0.00305	21.71	0.00126	17,230	11.68	NR
NS + NV	31.71	0.00299	1.95	0.00006	32,500	11.34	NR
Non Gavi vaccine price (CS + NV)
$11/dose	27.02	0.00300	19.00	0.00128	14,845	11.64	NR
$9/dose	24.25	0.00297	16.22	0.00133	12,202	11.52	NR
$7/dose	21.58	0.00298	13.45	0.00136	9900	11.52	NR
$5/dose	18.90	0.00301	10.72	0.00136	7897	11.57	R
Most efficient cervical cancer screening age (CS + NV)
30 years	18.23	0.00298	10.23	0.00129	7933	11.52	R
40 years	18.29	0.00303	10.20	0.00128	7947	11.79	R
50 years	19.37	0.00306	10.26	0.00127	8116	11.73	R

Cost-effectiveness threshold = US$ 9609.9/DALY averted

$\text{ICER}=\frac{\mathit{\text{Strategy}}cost‐\mathit{\text{Current}}\mathit{\text{scenario}}cost}{\mathit{\text{Current}}\mathit{\text{scenario}}\mathit{\text{DALYs}}\mathit{\text{lost}}‐\mathit{\text{Strategy}}\mathit{\text{DALYs}}\mathit{\text{lost}}}$

CS current scenario of opportunistic screening, NS National cervical cancer screening, NV National HPV vaccination, DALY disability adjusted life years, CC cervical cancer, R recommended, NR not recommended, Dom Dominated